Skip to main content
. 2017 Nov 24;8(65):109151–109160. doi: 10.18632/oncotarget.22642

Figure 6. CD122 mAb synergized with a tumor vaccine to inhibit the growth of B16-OVA tumors.

Figure 6

(A) On day +7 post-implantation, mice were treated with aCD122 mAb (administered 5 times at 2-3 day intervals) or with peptide vaccine (1 dose) or the combination as indicated. Mean tumor growth and survival are depicted (B). TILs were harvested at day +16, followed by analysis of percent of tumor infiltrating G-MDSCs, IFNγ/TNFα cytokine secreting CD8+ T cells upon ex-vivo stimulation with OVA257-264 peptide, OVA tetramer-specific CD8+ TILs, and Tregs. (C) On day +7 post-implantation, mice were treated with aCD122 in combination with peptide vaccine (3 doses) as indicated. Survival curve on the left shows primary treatment results; curve on the right shows rechallenged mice that rejected tumors after aCD122/vaccine treatment. Data are representative of 2-3 independent experiments. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. Error bars indicate SEM of n = 5/group for the bar graphs; n=10/group for the efficacy studies in B, and D.